The two drugs are metformin, one of the most widely used diabetes medications, and the GLP-1 class of medications that ...

The use of diabetes and weight-loss medications like Ozempic or Wegovy—called GLP-1 drugs—has exploded in recent years, with ...

Findings suggest semaglutide and other GLP-1 agonists may significantly reduce alcohol use disorder hospitalizations, ...

A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and accompanying ...

The GLP-1 tirzepatide, the active ingredient in Eli Lilly's Mounjaro, was found to reduce the risk of heart failure by 46% among individuals with obesity, according to a study published Nov. 16 in The ...

A new study supports the notion that the same mechanisms that help folks lose weight with Ozempic and its kin also work to ...

GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...

Mohammad Ali Sheffeh, MD, from the Mayo Clinic in Rochester, Minnesota, and colleagues examined the efficacy of GLP-1 RA or SGLT-2i initiation for reducing mortality or cardiovascular events among ...

As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new ...

There's a new player in the running game, and it's not the latest carbon-plated shoe or fancy GPS watch. GLP-1 medications ...

Some GLP-1 receptor agonists may hold promise as treatments for alcohol use disorder (AUD), a Swedish observational study ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...